Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas

摘要: To evaluate the efficacy of hypofractionated stereotactic radiotherapy performed as reirradiation in combination with fotemustine or bevacizumab salvage treatment patients recurrent malignant glioma. Between May 2006 and December 2013, 54 glioma received (HSRT, 25 Gy 5-Gy fractions) plus either at University Rome Sapienza, Sant’Andrea Hospital. All had Karnofsky performance score (KPS) ≥ 60 were previously treated standard chemoradiotherapy. Forty-two a GBM 12 an anaplastic astrocytoma (AA). The median overall survival (OS) time 12-month OS rates after HSRT was 11 months 30 % for 8.3 5 those (p = 0.01). Median PFS times 4 6 bevacizumab, respectively KPS > 70 0.04), AA histology, independent favourable prognostic factors OS. In general, both treatments well tolerated relatively low treatment-related toxicity. combined may represent feasible option progressive gliomas, although most tumors recur few months. Efficacy alkylating agents different radiation schedules needs to be evaluated prospective studies.